Richard Mulligan

Dr. Mulligan is the Mallinckrodt Professor of Genetics at Harvard Medical School and Director of the Harvard Gene Therapy Initiative. Dr. Mulligan received his B.S. from the Massachusetts Institute of Technology and his Ph.D. from the Department of Biochemistry at Stanford University School of Medicine. After receiving postdoctoral training at the Center for Cancer Research at MIT, Dr. Mulligan joined the MIT faculty and subsequently was appointed Professor of Molecular Biology and Member of the Whitehead Institute for Biomedical Research before moving to Children's Hospital and Harvard in 1996. Dr. Mulligan has been associated with a number of biotechnology companies, including Somatix Therapy Corporation (as founder, director, Scientific Advisory Board member and Chief Scientific Officer), Cell Genesys, Inc. (as Scientific Advisory Board member) and ImClone Systems Incorporated (as director and Scientific Advisory Board member). Dr. Mulligan is currently a director of Enzon Pharmaceuticals, Inc.